Anbio Biotechnology Class A Ordinary Shares (NNNN) Stock Analysis & Winston Score

Anbio Biotechnology is a Chinese medical diagnostics company that makes rapid test kits and point-of-care testing devices. Its products help doctors and clinics quickly detect infectious diseases, including respiratory illnesses and other conditions, without sending samples to a large laboratory. The company sells primarily to hospitals, clinics, and healthcare distributors, mainly across China and in select international markets. Anbio earns money by selling its diagnostic test kits and related equipment directly to healthcare providers and through distribution partners. The company operates mostly in China but has expanded exports to other countries, particularly during periods of high demand for infectious disease testing. Its high gross margin — above 86% — suggests strong pricing power on its proprietary test products, but the business faces real risk from revenue concentration: a significant portion of past sales came from COVID-19 related testing, and sustaining growth depends on successfully diversifying into other disease areas as pandemic-driven demand fades.